Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
By M. Davies, D. D’Alessio, J. Fradkin, W. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D. Wexler, John B. Buse. Diabetes Care, 2018
2,795 citations recorded by the source corpus.
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium–glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
Subfields: Endocrinology, Diabetes and Metabolism, Physiology
View Paper: https://www.semanticscholar.org/paper/1845ac53c5b63f4f094e4671ba7b3062f430f037
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. (2021, neutral): “lowing two strategies are offered (67):”
- 6. Glycemic Targets: Standards of Medical Care in Diabetes—2019 (2018, background): “If the patient is meeting A1C target, consider one of three strategies (39):”
- Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022, background): “With multiple interventions ubiquitously needed to optimize the care of people with diabetes and CKD, it is crucial to avoid therapeutic inertia.(30) Most patients with diabetes and CKD have high residual risks of CKD progression and cardiovascular disease despite treatment, and increasing options”